MSI-H/MMRd 和 MSS/pMMR

我们是谁

  • December 22, 2023
    Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
  • December 22, 2023
    CA102N 联合 TAS-102 与贝伐珠单抗联合 TAS-102 治疗复发性和/或难治性转移性结直肠癌受试者的 2 期研究比较
  • December 22, 2023
    A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
  • December 22, 2023
    RC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌
  • 2023 年 12 月 18 日
    Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
  • 2023 年 11 月 13 日
    针对晚期实体瘤患者的 TROP2 CAR 工程化 IL15 转导脐带血 NK 细胞剂量递增和扩增 1 期研究 (TROPIKANA)
  • 2023 年 10 月 31 日
    表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
  • October 17, 2023
    Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
  • October 17, 2023
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
  • 2023 年 8 月 31 日
    ELI-002 7P对KRAS/NRAS突变实体瘤受试者的研究